ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...

At a median follow-up of 61.4 months, enzalutamide plus ADT continued to show an improvement in OS vs ADT alone. Initial results from the phase 3 ARCHES trial (NCT02677896) showed an overall survival ...

The combination of sacituzumab govitecan and pembrolizumab demonstrated a 44.4% clinical complete response rate in muscle-invasive bladder cancer patients. The 12-month event-free survival and ...

Padeliporfin VTP therapy shows high efficacy with an 86.5% overall response rate and 73% complete response rate in low-grade UTUC. The therapy provides an organ-sparing alternative to ...

Hayne finds the emergence of antibody drugs conjugates in urothelial cancer to be particularly intriguing. Hayne is a professor of urology at the University of Western Australia and the head of ...